Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
The company has posted net profit of Rs.884.08 crores for the Financial Year ended March 31, 2022.
A post approval change order is often necessary, but innovators should plan and prepare for this pre-approval. Planning alongside outsourcing partners will help ensure that only a small-scale study is needed—not a new full clinical study
Cipla has reported consolidated financial results for the period ended March 31, 2022
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
The increase in PAT is driven by higher sales and lower marketing and depreciation charge vs the same period last year
The study, presented at the European Stroke Organisation Conference (ESOC 2022) pinpointed specific groups of bacteria associated with poorer neurological recovery from ischaemic stroke both in the acute phase (24 hours) and after three months
Subscribe To Our Newsletter & Stay Updated
